Citius Pharmaceuticals (CTXR) Assets Average (2011 - 2026)

Citius Pharmaceuticals (CTXR) has reported Assets Average for 16 consecutive years, with $137.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Assets Average rose 10.29% year-over-year to $137.4 million; the trailing twelve-month figure through Jun 2026 stood at $137.4 million (up 10.29% YoY), and the FY2025 full-year result was $123.8 million, up 12.41% from the prior year.
• Assets Average grew to $137.4 million in Q2 2026 per CTXR's latest filing, from $136.5 million in the prior quarter.
• Across five years, Assets Average topped out at $137.4 million in Q2 2026 and bottomed at $93.9 million in Q2 2024.
• Historically, Assets Average has averaged $117.1 million across 5 years, with a median of $117.9 million in 2022.
• The widest YoY moves for Assets Average: up 56.08% in 2022, down 19.38% in 2022.
• Over 5 years, Assets Average stood at $112.9 million in 2022, then retreated by 10.94% to $100.5 million in 2023, then increased by 18.08% to $118.7 million in 2024, then gained by 14.31% to $135.7 million in 2025, then advanced by 1.28% to $137.4 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $137.4 million, $136.5 million, and $135.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.